Skip to main content

Table 3 Bivariate regression model results, with time to lung cancer diagnosis as the outcome, for covariates to be considered for inclusion in the multivariable model

From: Statin use and lung cancer risk in chronic obstructive pulmonary disease patients: a population-based cohort study

Covariate

Hazard Ratio

95% Confidence Interval

p-value

Age

1.01

1.00

1.01

0.0011

Age Categories

  < 60

Ref

Ref

Ref

Ref

 [60, 70)

2.02

1.67

2.43

<.0001

 [70, 80)

2.33

1.95

2.80

<.0001

  ≥ 80

1.29

1.03

1.61

0.241

 Sex (Male)

1.39

1.24

1.56

<.0001

Health Authority

 Interior

1.29

0.98

1.71

0.0744

 Fraser

1.23

0.93

1.62

0.1485

 Vancouver Coastal

1.04

0.78

1.40

0.7687

 Vancouver Island

1.46

1.10

1.94

0.0084

 Northern

Ref

Ref

Ref

Ref

Income Quintile

 5

Ref

Ref

Ref

Ref

 4

1.27

1.03

1.57

0.0246

 3

1.14

0.92

1.41

0.2152

 2

1.23

1.00

1.50

0.0491

 1

1.24

1.02

1.51

0.0305

Total Number of Prescriptions

1.00

0.99

1.00

<.0001

Charlson Comorbidity Score (Continuous)

1.06

0.97

1.16

0.1853

Charlson Comorbidity Score (Categorical)

 0

Ref

Ref

Ref

Ref

 1

1.15

0.98

1.36

0.0931

 2

0.94

0.62

1.40

0.7459

  ≥ 3

0.90

0.55

1.48

0.6814

Inpatient Stay

3.57

3.16

4.03

<.0001

Number of hospitalizations

1.66

1.64

1.68

<.0001

COPD-related hospitalization

2.56

2.00

3.27

<.0001

CVD-related hospitalization

1.04

0.58

1.88

0.8958

Combination Therapy (ICS/LABA)

1.27

1.11

1.47

0.007

Number of physician encounters

1.02

1.02

1.02

<.0001

Oral glucocorticoid use

1.09

0.91

1.30

0.3399

  1. HR hazard ratio, AIC Akaike Information Criterion, CI confidence interval, LL lower limit, UL upper limit